MDMA

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Attention deficit hyperactivity disorder predominantly inattentive, Social, Autism spectrum, Spectrum, Clinical trial, University Hospital of Basel, ASCP, MDMA, ASD, Annual general meeting, NEO, Medicine, MindMed, Vaccine, Pharmaceutical industry

The Company plans to initiate its first clinical trial of MM-402 in 2023.

Key Points: 
  • The Company plans to initiate its first clinical trial of MM-402 in 2023.
  • This study demonstrated that administration of MM-402 increased social interaction in a characterized preclinical model of ASD.
  • MM-402 exhibited a robust effect on social interaction and was more potent than racemic MDMA with reduced hyperactivity effects.
  • Additional information about this trial is available on our website (mindmed.co) and on clinicaltrials.gov (identifier: NCT05277636).

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on: 
Friday, May 26, 2023
MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points: 
  • MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
  • Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
  • As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
  • Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Retrieved on: 
Thursday, May 25, 2023
Well, Psilocybin, Insurance, Partnership, Specialization, CPT, Prescription, COMPASS, American Medical Association, Ketamine, MDMA, MAPS, Physician, AMA, Current Procedural Terminology, TSX, Growth, FDA, Letter, News, III, Health insurance, Pharmaceutical industry, Nursing

In 2017, the FDA granted 'breakthrough' status to MDMA and phase 3 trials for MDMA-AT are underway or have been completed.

Key Points: 
  • In 2017, the FDA granted 'breakthrough' status to MDMA and phase 3 trials for MDMA-AT are underway or have been completed.
  • Numinus is excited to announce that it has welcomed its first Practitioner Partner, in Toronto, Ontario, through its recently launched Numinus Network™ program.
  • Numinus has recently completed several cost containment initiatives to refocus operations on revenue producing activities and to extend the Company's cash runway.
  • Collectively, these activities have reduced Numinus' annualized cash expenses by approximately $4.2 million, extending the Company's cash runway past anticipated MDMA approval.

New Research Finds Dramatic Increase in Illegal Ketamine Seized by Authorities, Sparking Concern About Potential Dangers of Rising Recreational Use

Retrieved on: 
Wednesday, May 24, 2023
Linda, Columbia University, Seizure, Nuffield Department of Population Health, Yale University, Telehealth, Depression, University, GHB, COVID-19, Fear, NYU, Ground substance, New York University Grossman School of Medicine, Research, Heroin, Bangladesh Technical Education Board, Government, NYU Langone Health, Dissociative, Cocaine, National Institute on Drug Abuse, Patient, Risk, Population health, Ketamine, Drug, MPH, Chronic pain, Fentanyl, JAMA Psychiatry, MDMA, Dietary supplement, Pharmaceutical industry, Health, Doctor of Philosophy

"Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."

Key Points: 
  • "Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."
  • He also warns that media and medical promotion of prescription ketamine in recent years is fueling black-market use and availability.
  • NDEWS continues to monitor the use and effects of ketamine and many novel drugs to alert the public about alarming trends in a timely manner.
  • The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Retrieved on: 
Wednesday, May 17, 2023
Psilocybin, GMP, CSE, Interview, FRA, TGA, Health Canada, Mental health, MDMA, Pharmaceutical industry, Psilocybe

In preparation for the international export, the Company harvested 300 kg of Psilocybe cubensis mushrooms at its Canadian GMP manufacturing facility in Princeton, British Columbia, Canada.

Key Points: 
  • In preparation for the international export, the Company harvested 300 kg of Psilocybe cubensis mushrooms at its Canadian GMP manufacturing facility in Princeton, British Columbia, Canada.
  • Medical-grade GMP psilocybin is set to be extracted from the mushrooms, processed, and shipped to Australia, where it will be sold to other licensed entities in the Australian medical market through Mind Medicine Australia and the Company’s representatives.
  • “The evidence-based decision by the TGA to reschedule psilocybin and MDMA is a positive step for the future of mental health and a monumental undertaking in logistics,” said Optimi Health CEO Bill Ciprick.
  • “To be entrusted as the exclusive supplier to Mind Medicine Australia, the largest Australian trainer of psychedelic-assisted therapy practitioners, is both an honour and a tremendous responsibility.

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Retrieved on: 
Tuesday, May 16, 2023
Psilocybin, GMP, Learning, CSE, Special access program, Research, SAP, Psychedelic drug, Joint venture, Shamanism, Capsule, Patient, Access, Health, Health Canada, MDMA, Pharmaceutical industry, MDXX

PharmAla has confirmed with Health Canada that this is the first-ever authorization of an MDMA-assisted therapy treatment under the Special Access Program.

Key Points: 
  • PharmAla has confirmed with Health Canada that this is the first-ever authorization of an MDMA-assisted therapy treatment under the Special Access Program.
  • Ultimately, that’s what all of our work should be about: improving lives for patients.” said Nick Kadysh, CEO of PharmAla.
  • Clinicians seeking to make a Special Access Program request for MDMA for their patients should submit a request directly to Health Canada’s Special Access Program.
  • Shaman Pharma will be distributing all Special Access Program requests for PharmAla.

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Retrieved on: 
Thursday, May 11, 2023
MDMC, REMS, MDAI, Depression, Therapy, MDEA, Mitigation, Methylone, Anxiety, Therapeutic index, Pathology, Pharmacokinetics, PCT, MDE, DSM-IV codes, Literature, OF, Patent, Patient, Post-traumatic stress disorder, USE, MBDB, Empathy, Salt, SALTS, MDMA, Safety, Pharmaceutical industry, Vaccine, Terran, PTSD

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.

Key Points: 
  • The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
  • Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
  • Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
  • Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.

Incannex enters a lease for first psychedelic-assisted psychotherapy clinic

Retrieved on: 
Friday, May 5, 2023
Psilocybin, ASX, Patient, MDMA, Nursing

Fit out and commissioning of these premises is due to commence shortly and is expected to be complete in August 2023, facilitating the opening of the first clinic shortly thereafter.

Key Points: 
  • Fit out and commissioning of these premises is due to commence shortly and is expected to be complete in August 2023, facilitating the opening of the first clinic shortly thereafter.
  • The clinic is designed as a commercial scale prototype, which can be scaled up and replicated to other locations.
  • Incannex has ordered an initial supply of psilocybin and MDMA, through an arrangement with Pharmala Biotech, to facilitate the commencement of clinical operations.
  • The estimated Australian market for psychedelic-assisted psychotherapy is anticipated to be more than $2bn per annum and the global market closer to $60bn.

ATMA to Provide Psychedelic-Assisted Therapy Training in French and Spanish in the Fall

Retrieved on: 
Thursday, May 4, 2023
Psilocybin, AB, Language, Mental, TCS, COVID-19, Chansons pour les pieds, SUD, Sindicato de Médicos de Asistencia Pública v Conselleria de Sanidad y Consumo de la Generalidad Valenciana, ATMA, Tongue, MDMA, TDM, Nursing

CALGARY, AB, May 4, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA"), Canada's leading psychedelic-assisted therapy training provider, will roll out the first full psychedelic training program in French and Spanish, highly focused on psilocybin and MDMA , this September.

Key Points: 
  • CALGARY, AB, May 4, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA"), Canada's leading psychedelic-assisted therapy training provider, will roll out the first full psychedelic training program in French and Spanish, highly focused on psilocybin and MDMA , this September.
  • To date, almost all psychedelic-assisted therapy training available has been in English, which excludes many interested healthcare providers from participating.
  • ATMA continues to move the psychedelic therapy revolution forward with inclusivity and encourages more healthcare providers to participate in the field of psychedelic therapy.
  • ATMA's French and Spanish program content is designed for all healthcare providers including therapists and prescribers alike, as there will be multiple roles to fill in order to provide safe and effective psychedelic-assisted therapy.

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

Retrieved on: 
Monday, May 1, 2023
Psilocybin, Agreement, International joint venture, GMP, Intellectual property, CSE, Authorization, Marketing, VIT, ASX, IP, Psychedelic drug, Joint venture, Sale, JV, Patient, Letter, MDMA, Dietary supplement, Property management, Pharmaceutical industry

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Australian-based Vitura Health Limited (ASX: VIT) (“Vitura”). Following the execution of a letter of intent between Vitura and PharmAla in late February, the parties have executed definitive agreements (the "Agreements"), including for the establishment of an incorporated joint venture vehicle, Cortexa Pty Ltd ("Cortexa"), which is owned equally by Vitura and PharmAla, pursuant to the terms of a joint venture agreement (the "JV Agreement") entered into among Cortexa, Vitura and PharmAla.

Key Points: 
  • VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Australian-based Vitura Health Limited (ASX: VIT) (“Vitura”).
  • Following the execution of a letter of intent between Vitura and PharmAla in late February, the parties have executed definitive agreements (the "Agreements"), including for the establishment of an incorporated joint venture vehicle, Cortexa Pty Ltd ("Cortexa"), which is owned equally by Vitura and PharmAla, pursuant to the terms of a joint venture agreement (the "JV Agreement") entered into among Cortexa, Vitura and PharmAla.
  • Cortexa is an Australian company, jointly owned by Vitura and PharmAla and with equal board representation.
  • In announcing the Joint Venture, Nick Kadysh, CEO of PharmAla Biotech, said:
    “In seeking a partner to be the market leading supplier of GMP manufactured MDMA and Psilocybin in Australia, we looked far and wide.